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Abstract
Background: Current evidence indicates that even low-level lead (Pb) exposure can have detrimental effects, especially in
children. We tested the hypothesis that Pb exposure alters gene expression patterns in peripheral blood cells and that these
changes reflect dose-specific alterations in the activity of particular pathways.
Methodology/Principal Finding: Using Affymetrix Mouse Genome 430 2.0 arrays, we examined gene expression changes in
the peripheral blood of female Balb/c mice following exposure to per os lead acetate trihydrate or plain drinking water for
two weeks and after a two-week recovery period. Data sets were RMA-normalized and dose-specific signatures were
generated using established methods of supervised classification and binary regression. Pathway activity was analyzed
using the ScoreSignatures module from GenePattern.
Conclusions/Significance: The low-level Pb signature was 93% sensitive and 100% specific in classifying samples a leave-
one-out crossvalidation. The high-level Pb signature demonstrated 100% sensitivity and specificity in the leave-one-out
crossvalidation. These two signatures exhibited dose-specificity in their ability to predict Pb exposure and had little overlap
in terms of constituent genes. The signatures also seemed to reflect current levels of Pb exposure rather than past exposure.
Finally, the two doses showed differential activation of cellular pathways. Low-level Pb exposure increased activity of the
interferon-gamma pathway, whereas high-level Pb exposure increased activity of the E2F1 pathway.
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Introduction
While substantial progress has been made in identifying the
alterations in cancer genomes, much less is understood of the
contributions of environmental agents in defining the course of
cancer development. Mounting evidence indicates a role for lead
in carcinogenesis. Epidemiological studies show that environmen-
tal and occupational lead exposures increase cancer risk,
particularly lung and stomach cancer [1–4]. There is also ample
evidence from animal studies that lead is carcinogenic, causing
lung, brain, hematopoietic and kidney tumors [5–7]. Furthermore,
recent studies have revealed several biological mechanisms that
might contribute to the carcinogenic effects of lead, including the
inhibition of DNA synthesis and repair, oxidative damage,
interaction with DNA-binding proteins and tumor suppressor
proteins and alterations to gene transcription [6–9]. Lead has also
been shown to damage chromosomes by causing micronuclei
formation, chromosomal aberrations and sister chromatid ex-
changes. [6,10]. Finally, lead enhances the carcinogenicity of other
genotoxic and mutagenic substances such as UV-radiation, oxygen
radicals and various chemical mutagens in the context of co-
exposure [11–15]. Therefore, lead exposure can cause the
deregulation of several cellular pathways that are critical for
normal cell division, DNA synthesis, DNA and damage repair and
gene transcription, setting the stage for tumorigenesis.
An ability to detect and quantify the effects of past and present
lead exposure on specific cellular pathways might facilitate the
monitoring of individuals for increased cancer risk and also
contribute to an understanding of how lead exposure contributes
to carcinogenesis. Current research emphasizes the need to evaluate
the mechanisms of lead-induced carcinogenesis, particularly oxida-
tive stress/apoptosis and the roles of cellular defense mechanisms,
signaling pathways, and intracellular lead-binding patterns.
Because children are especially susceptible to the effects of lead,
the Center for Disease Control and Prevention (CDC) has led
nationwide efforts to eliminate lead exposure in children. Although
Pb has been banned from gasoline, residential paint and solder
used for food cans and water pipes, the CDC estimates that over
300,000 U.S. children (ages 1–5 years) have elevated blood lead
levels (BLLs) [16]. Exposure is most likely to occur through
inhalation or ingestion of Pb dust or through exposure to soil or
water contaminated with Pb from industrial and manufacturing
sources. Pb poisoning in children can cause brain damage,
behavioral problems, growth delays, hearing problems, headaches
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set a goal to eliminate BLLs $10 mg/dL in young children by
2010. However, many studies indicate that even BLLs below
10 mg/dL can cause negative health effects [17–19] and the CDC
has stated that there is ‘‘no safe blood lead level’’ in children [16].
Accumulating evidence indicates that low-level Pb exposure can
have a detrimental effect on health, especially that of children. In
addition, many studies point to a role for Pb in facilitating
carcinogenesis. Therefore, sensitive tools are needed to be able to
detect past and present Pb exposures, even at low levels. In
addition to assessing individual exposure history, it is imperative to
be able to understand the biological mechanisms through which
Pb contributes to negative health outcomes, including increased
cancer risks. Therefore, two major challenges in the field of Pb
toxicology are to 1) evaluate the health impact of low-level
exposures that do not cause any observable health effects and 2)
understand the mechanisms by which Pb affects normal cellular
pathways and how this may contribute to future health risks.
Many groups are applying genomic tools to the study of Pb
toxicology. For example, Ruden et al. used expression quantitative
trait locus mapping techniques to identify genomic regions
containing putative ‘‘master-regulators’’ of response to Pb
exposure in fruit flies [20]. Bouton et al. [21] characterized gene
expression in immortalized astrocytes, thus confirming several
genes previously reported to be induced by lead and also
identifying some novel ones. This work prompted a follow up
study, which investigated the mechanisms by which Pb induced
vascular endothelial growth factor (VEGF) expression in astro-
cytes, demonstrating the potential for microarray studies to reveal
novel mechanisms of toxicity [22]. Finally, Kasten-Jolly et al. have
described the effects of developmental Pb exposure on gene
expression in the spleen [23]. The results of this study provided
insight into the role of Pb exposure on inhibition of heme
biosynthesis and the generation of peptides that could contribute
to autoimmune syndromes. It is vital to understand the effects of
Pb exposure on target tissues and organs, and the gene expression
patterns described in these studies serve as biomarkers of effect.
However, many of the tissues known to be affected by Pb (e.g.
spleen and brain tissues) are not easily accessible and thus do not
represent a means to assess exposure in a noninvasive manner.
Our study, which presents the first microarray analysis of the
effects of Pb exposure on PBCs, highlights the potential to use
blood-based biomarkers to identify low- and high-level exposures
and gain a better understanding of the underlying mechanisms of
Pb toxicity.
Previous studies have highlighted the opportunity to use gene
expression patterns in peripheral blood cells (PBCs) as a basis for
measuring exposure to environmental agents as well as a way to
probe the underlying mechanisms of toxicity. These studies
capitalize on the natural facility of PBCs as indicators of
environmental exposure combined with the power of global gene
expression analysis. For example, molecular signatures generated
to diagnose radiation exposure [24–26] also have the potential to
identify those genes that are affected by radiation exposure and
may have implications in the treatment of radiation injury. Many
other groups have described blood-based gene expression
signatures of occupational and environmental exposures [27–30].
We use a similar approach to develop signatures of Pb exposure
based on peripheral blood cell gene expression. However, our
approach is unique in that we have made use of a collection of
signatures that represent the activation of various cell-signaling
pathways to identify the pathways that are either activated or
repressed in response to Pb exposure. We describe dose-specific
signatures of Pb exposure in a mouse model and also identify
pathways that are perturbed in a dose-specific manner. These
findings suggest that the response to Pb exposure may be quite
distinct depending on the level of exposure. In addition, our results
confirm previous studies that suggest there is no safe level of Pb
exposure. Even low levels of Pb exposure alter normal gene
expression patterns in peripheral blood cells and result in the
aberrant activation of cellular signaling pathways.
Results
We generated blood-based gene expression signatures that
reflect changes in the transcriptome of peripheral blood cells. As
shown in Figure 1, we were able to generate robust signatures for
each dose of Pb exposure. Each signature demonstrated a strong
capacity to distinguish Pb-exposed mice from controls in a leave-
one-out crossvalidation. The low Pb signature (Figure 1A–B)
showed a sensitivity of 93% and specificity of 100% based on a
receiver-operator characteristic curve (AUC=0.9619, p-value
=0.0006340). The high Pb signature (Figure 1C–D) showed
100% sensitivity and specificity in classifying samples based on
exposure (AUC=1.000, p-value=0.0002173). It was also evident
from this analysis that the signatures were dose-specific. In other
words, the high dose signature could not accurately distinguish low
Pb exposure from control and vice versa (Figure 1B, D). Consistent
with this specificity, the 250-probe signatures only have 28 probes
in common. (Table S1 lists the probes in each signature along with
the corresponding gene symbol and description.)
A focus of the approach of developing gene expression
signatures of Pb exposure was the potential that this might
provide a method sensitive enough to reveal a history of exposure.
To evaluate the extent to which the signature persists following Pb
exposure, we analyzed the expression of the signature genes
following a two-week absence of Pb in the drinking water. As
shown in Figure 2, the effect was transient, with the expression of
the signature genes returning to the level of background after two
weeks of Pb-free drinking water. As such, it would appear that the
distinct expression signature resulting from Pb exposure reflects
the acute and current exposure to Pb rather than a lasting effect on
gene transcription patterns in the peripheral blood cells. The
normalized gene expression value for the genes in each signature
relative to control values is listed in Table S2.
In order to better understand the similarities and differences
between the two signatures, we broke each signature into two
components – genes that were either upregulated or downregu-
lated in response to Pb exposure – and compared these for each
dose. The high dose Pb signature was composed of 91 upregulated
probes and 159 downregulated probes. The low dose Pb signature
was composed of 170 upregulated probes and 80 downregulated
probes. A comparison of the upregulated probes revealed that the
signatures shared only 10 in common; a comparison of the
downregulated probes revealed that the signatures only shared 7 in
common (see Figure 3). Table S3 shows the top gene ontology
categories for the genes that are upregulated and downregulated in
response to each level of Pb exposure. An analysis of the gene
ontology categories that were significantly enriched in the
upregulated sets of genes revealed that although the genes induced
by the low and high doses of Pb did not overlap extensively, they
reflected similar biological processes, namely the cellular response
to unfolded proteins. However, the high-dose Pb signature also
includes several upregulated genes related to the processes of
angiogenesis and blood vessel formation. A similar analysis of the
gene ontology categories enriched in the downregulated genes
revealed that the high dose signature genes were related to the
cellular response to heat, and G-protein coupled receptor
Peripheral Blood Signatures of Lead Exposure
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represented anti-apoptotic genes and genes involved in antigen
presentation. A particularly interesting finding came from a
comparison of those genes downregulated in response to high
levels of Pb, but upregulated in response to low doses. This
particular subset of genes was enriched for binding sites for various
hormone receptors, such as androgen receptor, progesterone
receptor and glucocorticoid receptor (Table S4).
In light of the differences we observed between the low-dose and
high-dose Pb signatures, we hypothesized that Pb exposure could
result in differential activation or repression of cellular pathways
based on the level of exposure. To test this theory, we took
advantage of a collection of gene expression signatures represent-
ing the activity of particular cellular pathways [31,32]. We applied
this set of signatures to the gene expression data from Pb-exposed
mice and looked for pathways that were differentially regulated
based on level of exposure. As shown in Figure 4, the E2F1
pathway was found to be upregulated in the blood of mice exposed
to high doses of Pb relative to the low dose (p-value 0.0249, F-
value =4.126). We also observed a trend in which the interferon-
gamma (INFc) pathway was upregulated in the blood of mice
exposed to low doses of Pb as compared to the high dose (p-value
=0.0840, F-value =2.667).
Discussion
The concept of using the blood to assess Pb exposure is well-
established in the medical and public health fields. Measuring
Figure 1. Dose-Specific peripheral blood signatures. We generated signatures of lead exposure based on gene expression analysis of whole
blood from exposed mice and control mice. A) A 250-probe signature of low-dose lead exposure is shown as a heatmap, where each column
represents an individual biological sample and each row represents an Affymetrix M430 2.0 probe identifier. Red= high expression; blue = low
expression. B) The signature is able to accurately distinguish samples from control mice from those exposed to low levels of lead as shown in the
leave-one-out crossvalidation. However, this signature is specific to low level lead exposure, as there is no significant difference in predicted
probabilities of samples from control mice and those exposed to high-dose lead. C) A 250-probe signature of high-dose lead exposure is shown as a
heatmap of gene expression. D) While the signature is able to accurately distinguish between samples from control mice and mice exposed to high
levels of lead, it is unable to classify samples from mice exposed to low lead levels, demonstrating its dose specificity. Open purple circles = control
mice; close purple circles = mice exposed to low-level lead; open red circles = control mice; close red circles = mice exposed to high-dose lead.
doi:10.1371/journal.pone.0023043.g001
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Pb concentration. BLL is a measure of circulating Pb and does not
measure total Pb stored in the body. Nor does it measure the
effects of current or cumulative Pb exposure. Pb is also known to
impair heme biosynthesis. Therefore, an alternative method to
screen for Pb exposure is to measure the level of erythrocyte
protoporphyrin (EPP) or zinc protoporphyrin (ZPP), which is an
early and reliable indicator of impaired heme biosynthesis. This
method is not sensitive enough to be used to screen children, but
can be used in monitoring occupationally exposed adults and can
reflect average Pb exposure over a period of a few weeks. Our
approach, as outlined in Figure 1, was to measure global gene
expression in the blood of mice exposed to lead acetate via their
drinking water and to generate a signature based on the genes
most highly correlated with the exposure. Our hypotheses were
that 1) PBC gene expression signatures would be good indicators
of low-level Pb exposure which is not associated with observable
effects, but contributes to negative health outcomes, and 2) PBC
gene expression signatures may reflect past exposures, representing
an opportunity to characterize an individual’s exposure history
and its relationship to current health issues and future health risks.
We report robust and dose-specific blood-based signatures of Pb
exposure. The low-level Pb signature is particularly promising
because it represents an estimated BLL of 3.3 mg/dL, which is well
below the 10 mg/dL level for children set by the CDC. It is also
below the lower limits of detection for the EPP and ZPP tests. The
ability to detect such low-level Pb exposure could allow researchers
Figure 2. Transcriptional changes following exposure and recovery. A) Schematic of experimental design, in which mice were exposed to
lead via drinking water over the course of two weeks at which time a blood sample was collected. Then the lead source was removed and the mice
had a two-week recovery period before a second blood collection. B) The x-axis represents the 250 probes in the low-dose lead signature, ordered
from lowest to highest average expression value relative to controls. The y-axis represents the normalized average signal intensity of the probe across
the samples. The blue field represents the mean signal intensity of the signature probes in mice exposed to low-dose lead, normalized by subtracting
the mean values in the control mice. The magenta field represents the mean signal intensity of the same signature probes after the two-week
recovery period and normalized against controls. C) A comparison of the gene expression signature in mice following two weeks of exposure to high-
dose lead (blue) and then two weeks of recovery (magenta).
doi:10.1371/journal.pone.0023043.g002
Figure 3. Overlap between upregulated and downregulated
genes. Each signature was broken down into genes either upregulated
or downregulated in response to lead exposure compared to controls.
A) A Venn diagram comparing the upregulated gene lists from each
signature (high-dose lead, n=91; low-dose lead, n=170). We identified
10 overlapping upregulated genes. B) By comparing those genes
downregulated in response to each dose of lead, we identified 7
overlapping genes (high-dose lead, n=159; low-dose lead, n=80).
doi:10.1371/journal.pone.0023043.g003
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(both short-term and long-term).
Unfortunately, the signatures reported here do not seem to be
indicators of past exposure. However, the gene expression data
generatedprovide awealth ofmolecularinformationthat isusefulin
understanding the biological processes and signaling pathways
underlying the toxic effects of Pb at different doses. Many
toxicogenomic studies have analyzed transcriptome or gene
expression data using various annotation or pathway building tools.
We have used similar approaches to confirm some important genes
and pathways that have previously been implicated in Pb exposure,
such as the unfolded protein response, cell death processes,
angiogenesis and endocrine disruption. We observed the upregula-
tion of genes related to the unfolded protein response in both the
low and high Pb signatures. The unfolded protein response (UPR)
involves the transcription of chaperones used to aid in proper
protein folding and is known to be triggered by some toxicants,
including Pb, whichis thought to trigger the UPR through a
mechanism that involves inhibiting protein folding by substituting
for zinc or calcium ions [31]. Apoptotic cell death is known to play a
role in lead-induced neurotoxicity [33–35], and it is feasible that it
occurs in the peripheral blood even at low levels of exposure.
Additional anti-apoptosis genes are actually downregulated in the
low Pb signature, strengthening the argument that this low level of
exposure induces cell death in the PBCs. The high Pb signature also
included some upregulated genes related to angiogenesis and blood
vessel formation. This is consistent with work mentioned previously,
in which the mechanism of Pb-induced VEGF expression was
elucidated in astrocytes [21,22]. Interestingly, a subset of genes that
were upregulated in response to low doses of Pb and downregulated
inresponsetohighdosesofPbwassignificantlyenrichedforbinding
sites for various hormone receptors, such as androgen, progesterone
and glucocorticoid receptors. Although Pb is a known endocrine
disruptor, leading to reproductive impairment in vertebrates, the
mechanisms for this are not entirely clear and the effects of low-level
exposure are not well understood [36–39].
In addition to traditional gene annotation approaches, we also
use a novel approach to assess pathway activity by applying a panel
of gene expression signatures generated by specific perturbations in
controlled in vitro experiments to our dataset. Although use of this
panel of signatures is not new, its application to evaluating toxicant
exposure is. This approach allows us to assess the relative activity of
a given pathway across samples. This approach has been successful
in identifying the deregulation of oncogenic pathways in either
cancer cell lines or patient tumor samples and predicting which
targeted therapies might be most effective [32,40]. In the context of
Figure 4. Differential pathway activation. A) A heatmap displaying the predictions of pathway activity shows the predicted probability of
activation of a particular pathway (E2F1, IFN-gamma) across samples from mice exposed to different levels of lead. Red= high probability; blue =
low probability. B) Scatter plot of predicted E2F1 pathway activity for samples from mice exposed to low-dose lead (purple circles), high-dose lead
(red circles) or no lead (control, open circles). The x-axis represents the exposure group and the y-axis represents the probability that the E2F1
pathway is activated in an individual sample. C) Predicted probabilities for IFN-gamma pathway activity in mouse blood samples.
doi:10.1371/journal.pone.0023043.g004
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used as a tool for discovery to identify new pathways that are
affected by a particular toxicant or as a means of studying how
pathway activity varies depending on factors, such as level of
exposure, age, sex and co-exposure with other toxicants.
Our findings suggest that distinct biological processes are
involved in the response to Pb depending on the level of exposure.
Unlike the current methods used to assess Pb exposure, this
approach not only assesses exposure in a dose-specific manner but
it also provides information about the effects of the exposure on
cellular pathways and processes. At low levels of exposure, the
IFNc pathway is upregulated. This supports previous findings that
Pb inhibits IFNc production in a dose dependent fashion [41]
enhancing development of Th2 (Type 2 T helper cell) responses
versus Th1 (Type 1 T helper cell) responses [23,37]. Mechanistic
studies suggest that Pb selectively inhibits translation of IFNc [42].
IFNc plays a major role in immune system function by regulating
macrophage activation, differentiation of progenitor helper T cells
and enhancement of the major histocompatibility complex
molecule expression. INFc is known to have some immunomod-
ulatory effects and may be responsible for the disruption to the
various endocrine pathways observed in response to low-dose Pb
exposure. It is responsible for regulating cell-mediated immune
responses to infectious pathogens. It is also reported to have
antitumor activity. Even transient disruption of this pathway in
response to low levels of Pb exposure may have significant
consequences in terms of susceptibility to disease, including
infection, allergy and even cancer.
High Pb levels were found to enhance E2F1 pathway activity.
This is also supported by previous findings that suggest that Pb
exposure affects cell cycle and can actually increase DNA
synthesis. This has been observed in a variety of contexts. Pb
stimulated DNA synthesis in vascular smooth muscle cells [43] and
rat kidney cells [44]. Razani-Boroujerdi et al. [45] demonstrated
that Pb enhanced proliferation of rat splenic lymphocytes in vitro.
Furthermore, Lu et al. [46] has shown that Pb stimulates DNA
synthesis in human astrocytoma cells. Increases in cell proliferation
have also been observed in vivo in both rat kidney [47] and rat liver
[12,48]. This cumulative evidence for the role of Pb in enhancing
cell proliferation and DNA synthesis may have relevance to the
potential role of Pb in carcinogenesis.
Our work has demonstrated the ability to detect the effects of Pb
exposure on PBC gene expression, even at low levels of exposure.
Furthermore, we have shown that the IFNc and E2F1 pathways are
aberrantly regulated in response to low-level and high-level Pb
exposure respectively. These results underscore the importance of
understanding the effects of Pb exposure on critical cellular pathways.
By identifying the pathways that are impacted by Pb, we can better
understand the mechanisms underlying the negative health conse-
quences of Pb exposure and gain insight into the role of environmental
and occupational exposures in contributing to overall health.
Materials and Methods
Ethics Statement
Animal use and husbandry was conducted humanely and with
regard to alleviation of suffering in accordance with the Guide for
the Care and Use of Laboratory Animals and all procedures were
approved by Duke University Institutional Animal Care and Use
Committee (IACUC) under protocol number A122-08-05.
Murine Pb Exposure Study
Nine-week old female Balb/c mice (Jackson Laboratories, Bar
Harbor, ME) were divided into three groups. All mice received Pb-
free rodent chow. Each group received drinking water with
different concentrations of Pb in the form of lead acetate trihydrate
(Sigma Aldrich, St. Louis, MO) for a period of two weeks. The
control group (n=14) received 0 mg/mL; the low exposure group
(n=15) received mg/mL; and the high exposure group (n=15)
received 50 mg/mL. We chose these concentrations of Pb based on
previous studies by Iavicoli et al. [49], who found that the
relationship between the amount of Pb administered in the
drinking water and the resulting BLL after two weeks of exposure
could be represented by the following formula:
PbB(mg=dL)~328PbW (mg=L)z1:617
In this formula PbB is blood-lead concentration and PbW is water-
lead concentration [49]. Using this equation, we estimate the final
PbB concentration in the mice to be approximately 3.3 mg/dL in
the low-level exposure group 18 mg/uL in the high-level exposure
group. These levels would be in addition to any background levels
of Pb due to contamination of the drinking water. After two weeks
of exposure, peripheral blood was collected by submandibular
bleed from half of the control mice (n=7) and all of the exposed
mice (n=15 per group). All mice were then switched to Pb-free
drinking water for two additional weeks. A second blood sample
was collected after this recovery period (controls, n=7; low Pb,
n=15; high Pb, n=13). In the high Pb group, 1 mouse died
during the recovery period, and 1 blood sample was not used due
to contamination. All blood samples (72 total blood samples) were
collected using GoldenRod animal lancets (MEDIpoint, Inc.,
Mineola, NY) and stabilized using RNAProtect Animal Blood
Tubes and total RNA was extracted using the RNEasy Protect
Animal Blood Kit (Qiagen, Valencia, CA). Globin transcript was
removed using GLOBINclear for mice (Ambion, Austin, TX).
RNA Preparation and Microarray Analysis
Total RNA quality was assessed using an Agilent 2100
Bioanalyzer (Agilent, Palo Alto, CA). Each sample (150 ng) was
amplified using the MessageAmp Premier RNA Amplification Kit
(Ambion, Austin, TX) and analyzed using the Mouse Genome 430
2.0 Array (Affymetrix, Santa Clara, CA). The data discussed in
this publication are MIAME compliant and have been deposited
in NCBI’s Gene Expression Omnibus (GEO). The are accessible
through GEO Series accession number GSE28261 (http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE28261).
Statistical analysis
We compared gene expression profiles from whole blood
samples isolated from mice exposed to lead acetate through
drinking water or control mice. We generated a Pb exposure-
associated gene expression signature composed of a subset of genes
most correlated to Pb exposure by applying established methods of
supervised classification and binary regression [50] to data
normalized using the Robust Multi-array (RMA) method. The
data presented here are based on signatures composed of 250
Affymetrix probes for the purposes of comparing gene lists of
equivalent size. Optimal signatures for each dose (meaning the
signature used to achieve maximum accuracy in a leave-one-out
crossvalidation) may vary from those reported here. We calculated
the average probe expression value for each group of mice at each
timepoint (following exposure and recovery) and calculated the
level of gene expression as the difference between Pb-exposed mice
and controls for each timepoint.
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Gene Set Enrichment Analysis (GSEA, version 2.0.5) was used
as previously described [51,52]. Briefly, we used the gene set
annotation feature of GSEA (http://www.broadinstitute.org/
gsea/msigdb/annotate.jsp) to identify those gene sets that overlap
with the Pb signatures. These gene sets offer insights into the
functional annotation of our experimentally derived signatures and
have the potential to reveal the underlying biology of each
signature. First, we copied the list of the Affymetrix probe
identifiers comprising each signature generated by the binary
regression algorithm (genecoefficients.txt) and pasted it into the
browser’s query field. After selecting the appropriate identifier
platform (Affymetrix M430 2.0), we chose to compute overlaps
between each signature and the following: C2, or curated gene
sets, which is a collection of 1,892 curated gene sets; TFT, or
transcription factor targets, which includes 500 gene sets that
contain genes that share a transcription factor binding site defined
in the TRANSFAC (version 7.4, http://www.gene-regulation.
com/) database; and C5, which are gene sets that are named by
GO term and contain genes annotated by that term. We focused
on the top 20 gene sets in our efforts to annotate the biological
function of each signature.
Signature Annotation
In order to better understand the underlying biological response
represented by each Pb exposure signature, we used publicly
available tools to annotate each signature. Briefly, each signature
can be represented by a list of Affymetrix (M430 2.0 Array) probe
identifiers. This list was used as the input into GATHER (http://
gather.genome.duke.edu/) to generate the following annotations:
gene ontology (GO); KEGG (Kyoto Encyclopedia of Genes and
Genomes) pathways; and enrichment for transcription factor
binding sites (TRANSFAC v8.2 Professional). We also used the
Affymetrix NetAffx online batch query tool to translate each factor
from its list of M430 2.0 Array probe identifiers to gene symbols
and descriptions (https://www.affymetrix.com/analysis/netaffx/
index.affx).
Pathway Analysis
We analyzed the activity of several experimentally derived
pathway signatures as they related to our Pb exposure dataset.
Briefly, we used the ScoreSignatures module found on GenePat-
tern (https://cagt.igsp.duke.edu/gp/) to score a series of signa-
tures on our gene expression dataset. First, the RMA-normalized
data were translated from Affymetrix M430 2.0 probe identifiers
to HU133 Plus 2.0 using the FileMerger tool (http://filemerger.
genome.duke.edu/) and a bridging file from ChipComparer
(http://chipcomparer.genome.duke.edu/). We averaged gene
expression values for duplicated probes using an R script (by Jeff
Chang, see Supplemental Materials). The dataset file was then
saved in gct file format and uploaded to the GenePattern server.
After running the ScoreSignatures module, we plotted the
predicted pathway probabilities (probabilities.txt) for each path-
way in GraphPad Prism version 4.0b (GraphPad Software, Inc.,
La Jolla, CA). We tested whether the predicted probabilities for
each class were significantly different using a One-way ANOVA,
with Bonferroni’s Multiple Comparison Test to compare the
classes in a pairwise fashion.
Supporting Information
Table S1 Affymetrix HU133 Plus 2.0 probe identifiers from
each Pb signature and corresponding gene symbol, gene title and
GO biological process term.
(XLS)
Table S2 Normalized average signal intensity of all probes
comprising each signature. The Exposure column reflects gene
expression following 2 weeks of Pb exposure. The values represent
the mean signal intensity (RMA-normalized) across all samples
from the exposure group minus the mean signal intensity of the
samples from the control group. Likewise, the Recovery column
reflects gene expression following 2 weeks of Pb-free water. The
values represent the mean signal intensity of the samples from the
Pb-exposed mice minus the mean signal intensity of the samples
from the control mice.
(XLS)
Table S3 GO annotation terms for upregulated and downreg-
ulated genes in both high- and low-level Pb signatures.
(XLS)
Table S4 TRANSFAC annotations for those genes that are
upregulated in response to low-level Pb exposure, but downreg-
ulated in response to high-level Pb exposure.
(XLS)
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